European review for medical and pharmacological sciences
-
Eur Rev Med Pharmacol Sci · Jun 2019
Retracted PublicationLong noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Drug-resistance remains a huge problem in the therapy of malignant tumors including non-small cell lung cancer (NSCLC). Several researches have proved that long noncoding RNAs (lncRNAs) contributes to drug-resistance in NSCLC. LncRNA LUCAT1 was explored to identify how it functions in the cisplatin-resistance of NSCLC patients. ⋯ We suggest that LUCAT1 regulates cell cycle, cell apoptosis of NSCLC cells and the resistance to cisplatin through targeting IGF-2 and could be a possible target for NSCLC treatment.
-
Eur Rev Med Pharmacol Sci · Apr 2019
Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review.
Treatment of osteomyelitis, in of itself, is challenging but is further complicated by attendant bone infections. The management of bone infection, and bone rebuilding may be assisted by the use of bioactive glasses (BAGs) which have antimicrobial and osteo-stimulative proprieties. However, this clinical application and potential complications associated with BAGs (e.g., BAG S53P4), are poorly defined. The aim of this study is to review the results of clinical research using BAG S53P4 in the treatment of human bone infections. ⋯ BAG-S53P4 seems to be a useful bone filler in orthopaedic surgery for osteomyelitis treatment. The attendant clinical results and associated rate of complications associated with BAG S53P4 use are comparable with those of other techniques in the short term. However, long-term follow-up studies are required in order to confirm the longevity of this treatment.
-
Eur Rev Med Pharmacol Sci · Apr 2019
miR-940 promotes spinal cord injury recovery by inhibiting TLR4/NF-κB pathway-mediated inflammation.
The aim of this study was to investigate the effects of miR-940 and Toll-like receptor 4/Nuclear Factor κB (TLR4/NF-κB) pathways on inflammatory responses and spinal cord injury (SCI). ⋯ High expression of miR-940 can promote the recovery of spinal cord injury by downregulating the TLR4/NF-κB signaling pathway and inhibiting inflammation.
-
Eur Rev Med Pharmacol Sci · Mar 2019
LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
This study aims to elucidate the regulatory role of long noncoding RNA (lncRNA) LINC00673 in proliferative, invasive and metastatic capacities of papillary thyroid carcinoma (PTC), and to investigate the possible underlying mechanism. ⋯ High expression of LINC00673 in PTC predicts a poor prognosis. LINC00673 remarkably promotes the proliferation and invasion of PTC cells by inhibiting p53 expression by binding to EZH2 and DNMT1.
-
Eur Rev Med Pharmacol Sci · Feb 2019
Effect of isoflurane on myocardial ischemia-reperfusion injury through the p38 MAPK signaling pathway.
To investigate the effect of isoflurane on myocardial ischemia-reperfusion injury through the p38 mitogen-activated protein kinase (MAPK) signaling pathway. ⋯ Isoflurane can, through inhibiting the p38 MAPK signaling pathway, effectively protect the cardiac function of rats from myocardial ischemia-reperfusion injury, reduce the area of myocardial infarction, alleviate the pathological damage in myocardial cells and reduce the oxidative stress response.